COAG insider trading

Hemab Therapeutics Holdings, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
35
Last 90 days
32
Buys / sells
34% / 0%
Market cap

COAG insider activity at a glance

FilingIQ has scored 35 insider transactions for COAG since Jan 29, 2026. The most recent filing in our index is dated May 12, 2026.

Across the full history, 12 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on COAG insider trades is 54.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Latest COAG Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Frequently asked

How many insider trades does FilingIQ track for COAG?
FilingIQ tracks 35 Form 4 insider transactions for COAG (Hemab Therapeutics Holdings, Inc.), covering filings from Jan 29, 2026 onwards. 32 of those were filed in the last 90 days.
Are COAG insiders net buyers or net sellers?
Across the full Form 4 history for COAG, 12 transactions (34%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does COAG insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

Methodology & sources

Every COAG insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.